Drug safety and regulation. by Waller, Patrick C et al.
Waller, PC; Evans, SJW; Beard, K (2005) Drug safety and regula-
tion - New powers and resources are needed. BMJ, 331 (7507). p. 4.
ISSN 0959-8146 DOI: 10.1136/bmj.331.7507.4
Downloaded from: http://researchonline.lshtm.ac.uk/13307/
DOI: 10.1136/bmj.331.7507.4
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
receiving a weekly dose of around 1 MED to these sites
should be sufficient to prevent vitamin D insufficiency. If
only the face and hands are normally exposed, then a
weekly dose of about 2 MED would be required.
In 1994 we measured the sun exposure of 180
children and adolescents in three regions of England
during the spring and summer and found that 98.5%
and 91% of children and adolescents, respectively,
exceeded a weekly dose of 1 MED.6 Adolescents,
however, and especially teenage boys, generally expose
only their hands and face when outside: the prevalence
of weekly doses that exceeded 2 MED in this age group
was only 58%. The median time spent outdoors each
day by adolescents during those periods when the
weekly dose was less than 2 MED was 1.6 hours, rising
to 2.5 hours when the weekly dose exceeded 2 MED.
A popular perception is that being outdoors for
5-10 minutes, two or three times a week, in the summer
is sufficient for effective vitamin D production. The
reason why one to two hours outdoors each day was
insufficient in many cases to result in a cumulative
weekly dose of 2 MED, even though in the summer this
dose could be achieved by lying in unshaded sunshine
for about half an hour around noon, is that people are
generally upright, the sky is often cloudy in the UK and
buildings and trees often obscure direct sunlight and
part of the sky. All these factors serve to reduce the
intensity of sunlight on exposed skin thus necessitating
the need for prolonged exposure to acquire sufficient
dose. That the exposure to sunlight in many
adolescents may be insufficient in the spring and sum-
mer would certainly account for the observations that
the wintertime vitamin D status of almost all teenage
girls living in northern Europe is insufficient.7 The
association between low vitamin D levels in young
people and the subsequent risk of diseases such as
osteoporosis or cancer is not clear, however, so the
wider implications of this are uncertain.3 7
Such evidence that many adolescents are not suffi-
ciently exposed to the sun is not enough to justify
abandoning current awareness campaigns about skin
cancer, which are aimed primarily at avoiding excessive
exposure. This is especially true for children and
adolescents, for whom exposure to high levels of
sunlight strongly determines subsequently increased
risk of melanoma.8 This is a disease whose incidence is
predicted to continue rising in the UK for at least
another 30 years, even if current intervention strategies
eventually translate into a downturn in incidence.9
Furthermore, campaigns such as SunSmart are
intended to advise people primarily during recrea-
tional exposure for extended periods in strong
sunshine when measures to protect the skin, even if
they are used, will not be perfect and will still allow the
synthesis of vitamin D.10 So such campaigns should not
be abandoned, and British children and adolescents
need not deliberately spend extended periods in
strong sunshine. Rather, those whose lives are spent
almost entirely indoors, in the shade, or in vehicles
should take the opportunity during casual everyday
activities to walk on the sunny side of the street and,
when possible, to avoid taking the car.
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Drug safety and regulation
New powers and resources are needed
In the past few months, medical journals havepublished numerous editorials and news itemsrelating to drug safety and regulation.1–3 The
withdrawal of rofecoxib (Vioxx) has been the single big-
gest issue,4 but the cardiovascular safety of other
cyclo-oxygenase-2 (COX 2) inhibitors5 and possible sui-
cidal tendencies associated with selective serotonin
reuptake inhibitor (SSRI) antidepressants have also
raised considerable concerns.6 These high profile cases
have resulted in the regulatory bodies responsible for
drug safety coming under fire.
From reports in journals it would be easy to get the
impression that the US Food and Drug Administration
was uniquely at fault over the regulation of COX 2
inhibitors7 and the UK Medicines and Healthcare
products Regulatory Agency over paroxetine.3 Given
that the regulatory decisions made before and after the
marketing of these drugs have been similar throughout
the developed world, this can hardly be a logical
conclusion. Overall, regulators around the world use
similar systems and make similar decisions. If they all
get something wrong then it is probably the fault of
inadequacies in the underlying systems and, perhaps,
the science underpinning them.
We have been, and are, involved with drug
regulation in the United Kingdom. We believe that the
whole safety system for drugs might be improved,
going well beyond the processes of regulation itself.
For example, the pharmaceutical industry clearly has
an important role, although the extent and nature of its
influence have recently been called into question.8 It is
important to keep a perspective on where the existing
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system has come from, how it developed, and where it
is going. The current system began a little over 40 years
ago in the wake of the thalidomide disaster. Although it
has continued to evolve gradually, the basic principles
and powers laid down in the 1960s have not changed,
and adverse drug reactions remain an important cause
of morbidity and mortality.9
Drug usage can be made safer through advances in
safety science. A model for excellence in pharmaco-
vigilance has been proposed,10 and some principles
from that have gained widespread acceptance—for
example, the development of safety specifications and
pharmacovigilance plans for enhanced surveillance and
reporting of drug related harms. These principles, which
will become legal requirements in the European Union
later this year, focus particularly on how knowledge on
the safety of new drugs can be extended after marketing.
There is already an international guideline that is
based on these principles, produced by the International
Conference on Harmonisation,11 a body that brings
together government regulators and drug industry rep-
resentatives from the United States, the European
Union, and Japan to make international drug regulatory
processes more efficient and uniform. The International
Society for Pharmacoepidemiology, which provides a
forum for the open exchange of scientific information
and for the development of policy, education, and advo-
cacy in this field, has also considered these issues and
proposed ways to increase safety.12
The success of these improvements depends on the
strategic coordination of such work and the necessary
political support to make things happen. Drug safety,
however, is a political graveyard. The priority afforded to
this issue and the powers available to enforce it have
advanced very little in the past few decades, and influen-
tial politicians who might have championed the cause
have been conspicuously absent from the debate. Politi-
cal pressures exist to restrain public expenditure and
reduce regulation in health care generally, but if the goal
is greater safety through more effective regulation then
politicians should understand that new powers and
resources will be more important than focusing on the
effectiveness of regulators, looking for new people to do
the job, and proposing yet more organisational change.
In particular, although clear separation is sensible
between people responsible for licensing medicines
and those responsible for monitoring postmarketing
safety, the case for completely separate (and therefore
new) agencies has yet to be made. It would be more
logical to rethink the regulatory powers underpinning
postmarketing safety of drugs: these were enshrined in
law in the 1960s and have advanced little since.
Furthermore, policymakers and politicians inter-
nationally focus too much on the efficacy and cost
effectiveness of medicines at the expense of safety. It is
now time to grasp the nettle, improve the evidence
base on harms, and focus on regulating safety to at
least an equal extent.
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Attempts to prevent postnatal depression
Interventions have not included mental health workers, and have failed
Asystematic review published in this week’s BMJconcludes that the many psychosocial orpsychological interventions tested so far in
trials do not effectively prevent postnatal depression.1
Because this is an important disorder arising from
around one in eight births, the authors call for more
research on intensive support at home in the postnatal
period.1 As little as 20 years ago, however, there was
debate about whether postnatal depression was an
important problem at all. It was too often dismissed as
only a minor, transient problem with coping. So what
happened in the meantime to warrant these trials of
possible prevention?
In 1989 the prevalence of depression among
women eight months after birth in population based
surveys in Victoria, Australia, was 15.4% (95%
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